Personalis, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Feb 2026

PSNL

10-K: Personalis Reports 2025 Losses Amid Revenue Decline, Boosts Cash

Personalis, Inc. reported an 18% revenue decrease in 2025, driven by reduced enterprise sales, but strengthened its cash position and secured key Medicare coverage for its cancer diagnostic tests.

NASDAQ

27 Feb 2025

PSNL

Personalis, INC

10-K: Personalis, Inc. Reports FY2024 Results: Revenue Up 15% Driven by Pharma Growth

Personalis, Inc. announces a 15% increase in revenue for fiscal year 2024, primarily driven by growth in its pharmaceutical testing services.

NASDAQ

28 Feb 2024

PSNL

Personalis, INC

10-K: Personalis, Inc. Adopts 2020 Inducement Plan and Outlines Equity Award Terms

Personalis, Inc. establishes a 2020 Inducement Plan to grant various equity awards to new employees, aiming to incentivize their contributions and align their interests with the company's success.